Kolexia
Breysacher Gilles Gastro-entérologie
Breysacher Gilles
Gastro-entérologie
Hopital Albert Schweitzer
Colmar, France
63 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs colorectales Métastase tumorale Adénocarcinome Tumeurs du rectum Carcinomes Carcinome épidermoïde Tumeurs du côlon Tumeurs de l'anus Fatigue

Collaborateurs

Voir plus
Aparicio Thomas
Aparicio Thomas
Hôpital Avicenne, Bobigny, France
Lepage Come
Lepage Come
Hôpital François Mitterrand, Dijon, France
Bouche Olivier
Bouche Olivier
Hôpital Robert-Debré Reims, Reims, France
Lecomte Thierry
Lecomte Thierry
Hôpital Trousseau Chambray lès Tours, Chambray-lès-Tours, France

Industries

Voir plus
Servier
3 collaboration(s)
Dernière en 2021
B3TSI
1 collaboration(s)
Dernière en 2020
MundiPharma
1 collaboration(s)
Dernière en 2020
Roche
1 collaboration(s)
Dernière en 2020

Dernières activités

Voir plus
Panitumumab in combination with chemoradiotherapy for the treatment of locally-advanced anal canal carcinoma: Results of the FFCD 0904 phase II trial.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology   12 juin 2023
LBA28 Prognostic effect of imaging and CEA follow-up in resected colorectal cancer (CRC): Final results and relapse free survival (RFS) - PRODIGE 13 a FFCD phase III trial
Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022   01 septembre 2022
Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus: Phase I-II on Radiochemotherapy Combined With Panitumumab in the Treatment of Localised Epidermoid Carcinoma of the Anus
Essai Clinique (Fédération Francophone de Cancérologie Digestive)   23 mars 2022
Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma: Multicentric Randomized Phase III Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus 5-fluorouracil, Leucovorin, Irinotecan and Oxaliplatin (mFolfirinox) in Patients With Resected Pancreatic Adenocarcinoma
Essai Clinique (Unicancer)   03 janvier 2022
MRI-Based Radiomics Input for Prediction of 2-Year Disease Recurrence in Anal Squamous Cell Carcinoma.
Cancers   07 janvier 2021
Apport de la radiomique sur IRM pour prédire la réponse à 2 ans après chimioradiothérapie des cancers du canal anal localement évolués
31e Congrès national de la Société française de radiothérapie oncologique   01 octobre 2020
398O Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer (CRC) - PRODIGE 13 a FFCD phase III trial
Abstract Book of the ESMO Virtual Congress2020 19 – 21 September / 16 – 18 October 2020   01 septembre 2020
First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis: Phase II: First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis
Essai Clinique (Fédération Francophone de Cancérologie Digestive)   27 mars 2020
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study.
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver   30 décembre 2019
Nal-iri/lv5-fu versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study
Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September – 1 October 2019, Barcelona, Spain   01 octobre 2019